Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for spontaneous intracerebral hematoma
ChiCTR2200055889Phase 3Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intracerebral hemorrhage (ICH) comparing Atorvastatin 20 mg + standard treatment with Placebo + standard treatment (2 arms). Primary endpoint: Modified Rankin Scale (mRS) score at 8 weeks. Started Jan 2022; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR2200055889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055889.